Mineralys Therapeutics (MLYS) Treasury Shares (2022 - 2025)

Quarterly results put Treasury Shares at $125793.0 for Q4 2025, down 66.01% from a year ago — trailing twelve months through Dec 2025 was $125793.0 (down 66.01% YoY), and the annual figure for FY2025 was $125793.0, down 66.01%.

Mineralys Therapeutics has reported Treasury Shares over the past 4 years, most recently at $125793.0 for Q4 2025.

  • Treasury Shares reached $125793.0 in Q4 2025 per MLYS's latest filing, down from $370106.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.2 million in Q4 2022 and bottomed at $125793.0 in Q4 2025.
  • Median Treasury Shares over the past 4 years was $689018.0 (2023), compared with a mean of $675741.2.
  • The largest annual shift saw Treasury Shares decreased 15.95% in 2023 before it plummeted 66.01% in 2025.
  • Over 4 years, Treasury Shares stood at $1.2 million in 2022, then fell by 15.95% to $1.0 million in 2023, then tumbled by 63.28% to $370106.0 in 2024, then tumbled by 66.01% to $125793.0 in 2025.
  • Business Quant data shows Treasury Shares for MLYS at $125793.0 in Q4 2025, $370106.0 in Q4 2024, and $1.0 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Treasury Shares (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - 265,401.92
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 700,000.00
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 34.70 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Mineralys Therapeutics 2.50 Bn 2.50 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 125,793.00
Dec 31, 2025 125,793.00
Dec 31, 2024 370,106.00
Dec 31, 2024 370,106.00
Dec 31, 2023 1.01 Mn
Dec 31, 2023 1.01 Mn
Dec 31, 2022 1.20 Mn
Dec 31, 2022 1.20 Mn